Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.

Molecular cancer - 16 Apr 2014

Lassen Amanda, Atefi Mohammad, Robert Lidia, Wong Deborah Jl, Cerniglia Michael, Comin-Anduix Begonya, Ribas Antoni

Abstract excerpt

BACKGROUND: The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance. In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway can prevent emergence of resistance or provide additional growth inhibitory effects in vitro. METHODS: Anti-tumor effects of the combination of the BRAF inhibitor (BRAFi) dabrafenib and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to MAP Kinase Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Oximes

Share to Proto-Oncogene Proteins c-akt

Share to Pyridones

Share to Pyrimidinones

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 24735930
DOI: 10.1186/1476-4598-13-83
PMCID: PMC4021505

Genes

BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.PMID 24735930Read ↗

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.Semantic proximity Read ↗

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.Semantic proximity Read ↗

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.Semantic proximity Read ↗

AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.Semantic proximity Read ↗

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.Semantic proximity Read ↗

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.Semantic proximity Read ↗

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.Semantic proximity Read ↗

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.Semantic proximity Read ↗

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Semantic proximity Read ↗

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.Semantic proximity Read ↗

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by <i>NRAS</i> or <i>MEK</i> MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.